Antifungal dose adjustment in renal and hepatic dysfunction: Pharmacokinetic and pharmacodynamic considerations

被引：12

作者：

Cota J.M. ^{[1
]}

Burgess D.S. ^{[1
]}

机构：

[1] Department of Pharmacy Practice, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX 78209

来源：

Current Fungal Infection Reports | 2010年 / 4卷 / 2期

关键词：

Antifungal drugs; Dosage; Echinocandins; Kidney dysfunction; Liver dysfunction; Renal replacement therapy; Triazoles;

D O I：

10.1007/s12281-010-0015-9

中图分类号：

学科分类号：

摘要：

Adjusting the dose of antifungal agents for renal and hepatic impairment can be challenging given that clinicians must rely on limited pharmacokinetic data to derive specific regimens. These pharmacokinetic studies are typically performed in a small number of patients without invasive fungal infection, and results are not often reported in concert with accepted pharmacodynamic indices. This article aims to review pertinent pharmacokinetic studies of antifungal drugs in patients with renal or hepatic dysfunction. The impact of novel continuous renal replacement therapy techniques on the pharmacokinetic disposition of antifungal agents will also be described where data are available. Subsequently, this review provides recommendations for antifungal drug dosing in patients with kidney or liver dysfunction after accounting for established or emerging pharmacokinetic-pharmacodynamic relationships as they relate to antifungal drug efficacy in vivo. © 2010 Springer Science+Business Media, LLC.

引用

页码：120 / 128

页数：8

共 52 条

[1]

Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.-W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., Sylvester R., Rubin R.H., Wingard J.R., Stark P., Durand C., Caillot D., Thiel E., Chandrasekar P.H., Hodges M.R., Schlamm H.T., Troke P.F., De P.B., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, New England Journal of Medicine, 347, 6, pp. 408-415, (2002)

[2]

Pappas P.G., Rotstein C.M.F., Betts R.F., Et al., Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis, Clin Infect Dis, 45, pp. 883-893, (2007)

[3]

Cornely O.A., Maertens J., Winston D.J., Et al., Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia, N Engl J Med, 356, pp. 348-359, (2007)

[4]

Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling

[5]

Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling

[6]

Bergner R., Hoffmann M., Riedel K.D., Et al., Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): Need for a high daily dose of 800 mg, Nephrol Dial Transplant, 21, pp. 1019-1023, (2006)

[7]

Fuhrmann V., Schenk P., Jaeger W., Et al., Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration, J Antimicrob Chemother, 60, pp. 1085-1090, (2007)

[8]

Heintz B.H., Matzke G.R., Dager W.E., Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis, Pharmacotherapy, 29, pp. 562-577, (2009)

[9]

Andes D., Van O.M., Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model, Antimicrobial Agents and Chemotherapy, 43, 9, pp. 2116-2120, (1999)

[10]

Baddley J.W., Patel M., Bhavnani S.M., Et al., Association of fluconazole pharmacodynamics with mortality in patients with candidemia, Antimicrob Agents Chemother, 52, pp. 3022-3028, (2008)

← 1 2 3 4 5 6 →